CAMBRYN BIOLOGICS ANNOUNCES EXPANSION OF ITS MANUFACTURING FACILITY

SARASOTA, Florida – December 14, 2016, Mark P. Famiglio, CEO of Cambryn Biologics, a privately held Delaware corporation, announces that the Company has begun in January 2017, the construction and expansion of its current plasma manufacturing facility.

CAMBRYN BIOLOGICS ANNOUNCES COMPLETION OF CONTRACT DEVELOPMENT MANUFACTURING AGREEMENT AND FILING OF PATENT

SARASOTA, Florida – September 5, 2016, Mark P. Famiglio, CEO of Cambryn Biologics, a privately held Delaware corporation, announces that the Company has added additional scientific staff to complete the development of two plasma derived therapeutic products announces earlier in February of this year

CAMBRYN BIOLOGICS ANNOUNCES NEW PRODUCT DEVELOPMENT

SARASOTA, Florida –January 31, 2016, Mark P. Famiglio, CEO of Cambryn Biologics, a privately held Delaware corporation, announces that the Company has initiated its internal research and development of plasma derived therapeutic products.

CAMBRYN BIOLOGICS ANNOUNCES COMPLETION OF CONTRACT DEVELOPMENT MANUFACTURING AGREEMENT AND FILING OF PATENT

SARASOTA, Florida –November 15, 2015, Mark P. Famiglio, CEO of Cambryn Biologics, a privately held Delaware corporation, announces that the Company successfully completed a Contract Development Agreement with Abeona Pharmaceuticals, and accordingly filed a provisional patent; the agreement provided a non-exclusive license agreement to the technology.

CAMBRYN BIOLOGICS ANNOUNCES KEY HIRINGS OF TWO SENIOR DIRECTORS
SARASOTA, Florida – May, 2013, Mark P. Famiglio, CEO of Cambryn Biologics, a privately held Delaware corporation, announces key hirings of two senior directors. Mr. Joseph Buettner, Director of Process Development and R & D. Mr. Buettner has over 27 years of experience in Research and Development of Biopharmaceuticals.

Cambryn Biologics LLC

Cambryn Biologics LLC is a Delaware corporation having its principal facility and offices in Sarasota, Florida. Cambryn is an emerging biotherapeutic company dedicated to the development, manufacturing and commercialization of biologic products for the management and treatment of clotting factor deficiencies.

logo small

State-of-the-Art Manufacturing Facility

Our facility consists of 50,000 square feet, located adjacent to the Sarasota/Bradenton International Airport, Sarasota, Florida, USA. Cambryn Biologics operates a state-of-the-art manufacturing facility.

Contact Details

Address: 600 Tallevast Rd.
Suite 201 Sarasota, FL 34243

Phone: (941) 355-7400

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.